| abstract |
Genetically modified cells that continuously express HLA-G (eg, cell surface HLA-G), and nucleic acid compositions for generating such genetically modified cells, are disclosed herein. Methods of cell therapy using genetically modified cells that consistently express HLA-G are also disclosed. The HLA-G genetic modifications described herein provide cells with the characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells are universal or improved for organ transplantation, cell and tissue regeneration or repair, and other treatments. It has the potential to become a donor cell. |